# Ovarian Neoplasms FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/ovarian-neoplasms

> 6 upcoming FDA catalysts in ovarian Neoplasms: mocertatug rezetecan (GSK) on Sep to Dec 2029 (topline data readout); mocertatug rezetecan (GSK) on September 2029 (primary completion); mocertatug rezetecan (mo-rez, GSK) on May to Aug 2030 (topline data readout); mocertatug rezetecan (mo-rez, GSK) on May 2030 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep to Dec 2029 | [Mocertatug rezetecan topline data readout](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Ovarian Neoplasms | scheduled | "NCT07694427 (Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07694427)) |
| September 2029 | [Mocertatug rezetecan primary completion](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Ovarian Neoplasms | scheduled | "NCT07694427 (Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07694427)) |
| May to Aug 2030 | [Mocertatug rezetecan (mo-rez) topline data readout](https://sec-api.dev/pdufa/mocertatug-rezetecan-mo-rez) | GSK | Ovarian Neoplasms | scheduled | "NCT07684612 (A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-21 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684612)) |
| May 2030 | [Mocertatug rezetecan (mo-rez) primary completion](https://sec-api.dev/pdufa/mocertatug-rezetecan-mo-rez) | GSK | Ovarian Neoplasms | scheduled | "NCT07684612 (A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-21 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684612)) |
| Jul to Oct 2030 | [Mocertatug rezetecan topline data readout](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Ovarian Neoplasms | scheduled | "NCT07286266 (A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-22 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286266)) |
| July 2030 | [Mocertatug rezetecan primary completion](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Ovarian Neoplasms | scheduled | "NCT07286266 (A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-22 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286266)) |

## Drugs

- [Mocertatug rezetecan](https://sec-api.dev/pdufa/mocertatug-rezetecan) (GSK)
- [Mocertatug rezetecan (mo-rez)](https://sec-api.dev/pdufa/mocertatug-rezetecan-mo-rez) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/ovarian-neoplasms.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ovarian Neoplasms FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/ovarian-neoplasms

```bibtex
@misc{secapidev_indications_ovarian_neoplasms_20261116,
  title        = {Ovarian Neoplasms FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/ovarian-neoplasms}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_ovarian_neoplasms_20261116","title":"Ovarian Neoplasms FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/ovarian-neoplasms","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
